![Dirk Buscher](https://d2cax41o7ahm5l.cloudfront.net/cs/speaker-photo/Chemotherapy-2015-Dirk-Bscher--23355.jpg)
Dirk Buscher
Gri-Cel, Spain
Biography
Dirk Büscher received his PhD in Biology in the area of Immunology from the University of Hannover, Germany, and focused his postdoctoral work at the Salk Institute, La Jolla, California, on molecular developmental biology and stem cell research. In 2004, he joined Cellerix SL and moved up to the position of Vice President of R&D representing the company in several scientific advices at EMA. Additionally he served as industry expert on mesenchymal stem cells in internal EMA workshops. In 2007 he obtained an International Executive MBA from the Instituto de Empresa (IE). 2010 He accepted a position as chief executive officer of Gri-Cel SA, a newly created fully owned subsidiary of Grifols SA, dedicated to advanced therapies and innovative therapeutic approaches. He currently serves on the boards of VCN Bioscience, Araclon Biotech, and TiGenix NV.
Abstract
Abstract : Molecularly targeted therapy for metastatic melanoma